Back to search
FDAFDA · Food and drugs·Recall number D-0825-2018

Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles, NDC 0378-7050-01

Published May 30, 2018 · Recall initiated: April 24, 2018

Summary

FDA records drug Class II recall D-0825-2018, published May 30, 2018 and initiated April 24, 2018. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 11,650 bottles; Lot: NDC 0378-7050-01 Lot Numbers: 3079386, Exp. 10/31/18 3079387, Exp. 10/31/18 3079388, Exp. 10/31/18 3083762, Exp. 3/31/19 3083763, Exp. 3/31/19 3083764, Exp. 3/31/19 3083765, Exp. 3/31/19 3083766, Exp. 3/31/19 3083767, Exp. 3/31/19. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Product was distributed throughout the United States, including Puerto Rico.
Lot
NDC 0378-7050-01 Lot Numbers: 3079386, Exp. 10/31/18 3079387, Exp. 10/31/18 3079388, Exp. 10/31/18 3083762, Exp. 3/31/19 3083763, Exp. 3/31/19 3083764, Exp. 3/31/19 3083765, Exp. 3/31/19 3083766, Exp. 3/31/19 3083767, Exp. 3/31/19
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles, NDC 0378-7050-01 recalled?

Yes. FDA published recall D-0825-2018 on May 30, 2018. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter